IFN-γ-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma

Clinical Cancer Research

Volumn 3, Issue 4, 1997, Pages 573-578

  Seliger, Barbara ^a   Hammers, Silke ^a   Höhne, Alexandra ^a   Zeidler, Reinhard ^b   Knuth, Alexander ^c   Gerharz, Claus Dieter ^d   Huber, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Forschungszentrum F Umwelt Und G   (Germany)

^c Nordwest Hospital   (Germany)

^d Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, RENAL CELL; CYSTEINE ENDOPEPTIDASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; KINETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030964320     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Zinkernagel, R. M., and Doherty, P. C. MHC restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity, function and responsiveness. Adv. Immunol., 27: 51-77, 1979.
2. Goldberg, A. L., and Rock, K. L. Proteolysis, proteasomes and antigen presentation. Nature (Lond.), 357: 375-378, 1992.
3. Ortiz-Navarette, V., Seelig, A., Gernold, M., Frentzel, S., Kloetzel, J. M., and Hämmerling, G. J. Subunit of the "20S" proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature (Lond.), 353: 663-665, 1991.
4. Trowsdale, J., Hanson, I., Mockridge, I., Beck, S., Townsend, A., and Kelly, A. Sequence encoded in the class II region of the MHC related to the "ABC" superfamily of transporters. Nature (Lond.), 348: 741-744, 1990.
5. Hill, A., and Ploegh, H. L. Getting the inside out: the transporter associated with antigen processing (TAP) and the presentation of viral antigen. Proc. Natl. Acad. Sci. USA, 92: 341-343, 1995.
6. Attaya, M., Jameson, S., Martinez, C. K., Hermel, E., Aldrich, C., Forman, J., Fischer-Lindahl, K., Bevan, M., and Monaco, J. J. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature (Lond.), 355: 647-649, 1992.
7. Neefjes, J. J., Momburg, F., and Hämmerling, G. J. Selective and ATP-dependent translocation of peptides by MHC-encoded transporter. Science (Washington DC), 261: 769-771, 1993.
8. Androlewicz, M. J., Anderson, K. S., and Cresswell, P. Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proc. Natl. Acad. Sci. USA, 90: 9130-9134, 1993.
9. Schumacher, T. N. M., Kantesaria, D. V., Heemels, M. T., Ashton-Rickardt, P. G., Shepherd, J. C., Feüh, K., Young, Y., Peterson, P. A., Tonegawa, S., and Ploegh, H. L. Peptide length and sequence specificity of mouse TAP1/TAP2 translocator. J. Exp. Med., 179: 533-540, 1994.
10. Momburg, F., Roelse, J., Howard, J. C., Butcher, G. W., Hämmerling, G. J., and Neefjes, J. J. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature (Lond.), 367: 648-651, 1994.
11. Mausdley, D. J., and Pound, J. S. Modulation of MHC antigen expression by viruses and oncogenes. Immunol. Today, 72: 429-431, 1991.
12. Tanaka, K., Isselbacher, A., Khoury, G., and Jay, G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science (Washington DC), 225: 26-30, 1985.
13. Ferrons, S., and Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16: 487-494, 1995.
14. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mule, J., Rosenberg, S. A., and Bennink, J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272, 1993.
15. Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. L. M., and Walboomers, J. M. M. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179: 335-340, 1994.
16. Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D. M., and Simons, J. W. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst., 87: 280-285, 1994.
17. Seliger, B., Höhne, A., Knuth, A., Bernhard, H., Meyer, T., Tampé, R., Momburg, F., and Huber, C. Analysis of the MHC class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res., 56: 1756-1760, 1996.
18. Epperson, D. E., Arnold, D., Spies, T., Cresswell, P., Pober, J. S., and Johnson, D. R. Cytokines increase transporter in antigen processing- 1 expression more rapidly than HLA class I expression in endothelial cells. J. Immunol., 149: 3297-3301, 1992.
19. Shimbara, N., Orino, E., Sone, S., Ogura, T., Takashina, M., Shono, M., Tamura, T., Yasuda, H., Tanaka, K., and Ichihara, A. Regulation of gene expression of proteasomes (multi-protease complexes) during growth and differentiation of human hematopoietic cells. J. Biol. Chem., 267: 18100-18109, 1992.
20. Gaczynska, M., Rock, K. L., and Goldberg, A. L. Gamma Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (Lond.), 365: 264-267, 1993.
21. Boes, B., Hengel, H., Ruppen, T., Multhaup, G., Koszinowski, H. U., and Kloetzel, P. M. Interferon-gamma stimulation modulates the proteolytic activity and cleavage site preference of the 20S proteasomes. J. Exp. Med., 179: 901-909, 1994.
22. Wright, K. L., White, L. C., Kelly, A., Beck, S., Trowsdale, J., and Ting, J. P. Y. Coordinate regulation of the human TAP-1 and LMP-2 genes from a shared bidirectional promoter. J. Exp. Med., 181: 1459-1471, 1995.
23. Seliger, B., Höhne, A., Knuth, A., Bernhard, H., Tampé, R., Gerharz, K. D., and Huber, C. Reduced membrane MHC class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res., 2: 1427-1433, 1996.
24. Spies, T., Bresnahan, M., Bahram, S., Arnold, D., Blanck, G., Mellins, E., Pious, D., and DeMars, R. T. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature (Lond.), 348: 744-747, 1990.
25. Brodsky, F. M., Parham, P., Barn, C. J., Crumpton, M. J., and Bodmer, W. F. Monoclonal antibodies for analysis of the HLA system. Immunol. Rev., 47: 342-367, 1979.
26. van Endert, P. M., Tampé, R., Meyer, T. H., Tisch, R., Bach, J. F., and McDevitt, H. O. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity, 1: 491-500, 1994.
27. Towbin, H. S., Staehelin, J., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4344-4350, 1979.
28. Sugita, K., Miyazaki, J., Appella, E. and Ozato, K. Interferons increase the transcription of a major histocompatibility class I gene via a 5′ Interferon consensus sequence. Mol. Cell. Biol., 7: 2625-2630, 1987.
29. + T cells. Cell, 71: 1205-1214, 1992.
30. Fehling, H. J., Swat, W., Laplace, C., Kühn, R., Rajewsky, K., Müller, U., and von Boehmer, H. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science (Washington DC), 265: 1234-1237, 1994.
31. Min, W., Pober, J. S., and Johnson, D. R. Kinetically coordinated induction of TAP1 and HLA class I by IFN-γ. J. Immunol., 156: 3174-3183, 1996.
32. Krown, S. E. J. Interferons in malignancy: biological products or biological response modifiers? J. Natl. Cancer Inst., 59: 306-309, 1988.
33. Palmer, P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R., and Franks, C. R. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol., 3: 475-480, 1992.
34. Figlin, R. A., Pierce, W. C., and Bellegrun, A. Combination biological therapy with interleukin-2 and interferon-alpha in the outpatient treatment of metastatic renal cell carcinoma. Semin. Oncol., 20: 11-15, 1993.
35. Aulitzky, W. E., Schuler, M., Peschel, C., and Huber, C. Clinical pharmacology and therapeutic use of IFN-gamma. Drugs, 48: 667-677, 1994.
36. Aulitzky, W. E., Grosse-Wilde, H., Westhoff, U., Tilg, H., Aulitzky, W., Gastl, G., Herold, M., and Huber, C. Enhancement of serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma. Clin. Exp. Immunol., 86: 236-239, 1991.
37. Aulitzky, W. E., Aman, J., Seliger, B., and Huber, C. Mechanism of action of interferon-gamma in renal cell carcinoma: preclinical and clinical data. Anticancer Drugs, in press, 1997.